DDInter504 DDInter224
Desipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, desipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Secondary amine TCAs, such as desipramine and nortriptyline, are more potent inhibitors of norepinephrine reuptake than tertiary amine TCAs, such as amitriptyline and doxepine. TCAs also down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use
Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein.[A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving remission. Second-generation BCR-ABL inhibitors like bosutinib inhibit most resistance-conferring BCR-ABL mutations except V299L and T315, thus providing more therapeutic options for patients.[A6901,A17961] Bosutinib was first approved by the FDA in 2012 for the treatment of adult chronic, accelerated, or blast-phase Ph+ CML with resistance or intolerance to prior therapy. On September 26, 2023, bosutinib was also approved by the FDA for the treatment of pediatric CML that is newly diagnosed or resistant/intolerant to prior therapy. This approval was based on favorable results obtained from the open-label, randomized, multicenter trial BFORE that showed a significant improvement in major molecular response, defined as a ≤0.1% BCR ABL ratio on an international scale, with bosutinib treatment.
Desipramine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Bosutinib
Desipramine {u} (Compound) upregulates {v} (Gene) INSIG1
INSIG1 {u} (Gene) is upregulated by {v} (Compound) Bosutinib
Desipramine {u} (Compound) causes {v} (Side Effect) Decreased appetite
Decreased appetite {u} (Side Effect) is caused by {v} (Compound) Bosutinib
Desipramine {u} (Compound) resembles {v} (Compound) Atomoxetine
Atomoxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bosutinib
Desipramine {u} (Compound) resembles {v} (Compound) Oxcarbazepine
Oxcarbazepine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bosutinib
Desipramine {u} (Compound) resembles {v} (Compound) Carbamazepine
Carbamazepine {u} may lead to a major life threatening interaction when taken with {v} Bosutinib
Desipramine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Gefitinib
Gefitinib {u} (Compound) resembles {v} (Compound) Bosutinib
Desipramine {u} (Compound) upregulates {v} (Gene) INSIG1
INSIG1 {u} (Gene) is regulated by {v} (Gene) HCK
HCK {u} (Gene) is bound by {v} (Compound) Bosutinib
Desipramine {u} (Compound) upregulates {v} (Gene) FDFT1
FDFT1 {u} (Gene) regulates {v} (Gene) PTK2B
PTK2B {u} (Gene) is bound by {v} (Compound) Bosutinib
Desipramine {u} (Compound) causes {v} (Side Effect) Decreased appetite
Decreased appetite {u} (Side Effect) is caused by {v} (Compound) Gefitinib
Gefitinib {u} (Compound) resembles {v} (Compound) Bosutinib
Desipramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bosutinib (Compound)
Desipramine (Compound) upregulates INSIG1 (Gene) and INSIG1 (Gene) is upregulated by Bosutinib (Compound)
Desipramine (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Bosutinib (Compound)
Desipramine (Compound) resembles Atomoxetine (Compound) and Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Desipramine (Compound) resembles Oxcarbazepine (Compound) and Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Desipramine (Compound) resembles Carbamazepine (Compound) and Carbamazepine may lead to a major life threatening interaction when taken with Bosutinib
Desipramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Gefitinib (Compound) and Gefitinib (Compound) resembles Bosutinib (Compound)
Desipramine (Compound) upregulates INSIG1 (Gene) and INSIG1 (Gene) is regulated by HCK (Gene) and HCK (Gene) is bound by Bosutinib (Compound)
Desipramine (Compound) upregulates FDFT1 (Gene) and FDFT1 (Gene) regulates PTK2B (Gene) and PTK2B (Gene) is bound by Bosutinib (Compound)
Desipramine (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Gefitinib (Compound) and Gefitinib (Compound) resembles Bosutinib (Compound)